For female patients and stage Ib cancer patients treated within the Traditional Chinese Medicine group, the mOS duration was found to be longer than in the non-Traditional Chinese Medicine group (p<0.0001 and p<0.0001, respectively), as revealed by subgroup analysis.
Patients with stage I GC who have high-risk factors could see their survival times improved through the application of TCM treatment.
Patients with stage I GC and high-risk factors may experience improved survival outcomes through TCM treatment.
A study exploring how the combined treatment of Zhenggan Huayu decoction (ZGHY) and entecavir (ETV) affects the gut microbiota in individuals with chronic hepatitis B (CHB) fibrosis.
A total of 59 participants, each suffering from CHB-related fibrosis, were enrolled and treated with a combination of ZGHY and ETV, or with ETV alone. garsorasib Fecal samples from patients at weeks 0, 12, and 24 after treatment were analyzed using 16S rRNA gene sequencing, providing insights into the gut microbiota.
A 24-week treatment period resulted in a higher microbiota diversity in the ZGHY + ETV group than in the ETV group. A variety of potentially harmful bacterial species, encompassing species, species, and species, necessitate consideration. The microbial makeup of the ZGHY + ETV group exhibited a reduction in certain species, in stark contrast to an increase in beneficial bacteria, including spp., spp., and other helpful species.
Observations of the Traditional Chinese Medicine (TCM) group did not consistently show decreases in pathogenic bacteria and increases in probiotics; for instance, some samples contained a substantial amount of pathogenic bacteria. ZGHY, a supplementary Traditional Chinese Medicine (TCM) regimen for ETV, played a constructive role in handling CHB patients' conditions.
The Traditional Chinese Medicine (TCM) group did not consistently exhibit reduced pathogenic bacteria or increased probiotic counts (e.g., abundance was inconsistent). For CHB patients receiving ETV treatment, the integration of ZGHY, a Traditional Chinese Medicine formulation, displayed a favorable effect.
A clinical trial to evaluate the impact of Xiangsha Liujun pills on digestive function recovery and safety in COVID-19 convalescents.
A double-blind, randomized, placebo-controlled clinical trial was conducted with a randomized study design. Our study, conducted at Ezhou Hospital of Traditional Chinese Medicine, encompassed 200 COVID-19 patients in the recovery phase. By means of random assignment, 200 subjects were divided into two groups, 100 in each: a treatment group, administered Xiangsha Liujun pills, and a control group, given a placebo. Subjects were given Xiangsha Liujun pills or placebo to ingest orally three times a day for a duration of two weeks. At the outset (week 0), midway (week 1), and at the end (week 2) of the intervention, each qualifying patient was scheduled for a visit. The treatment and control groups were assessed to evaluate the effectiveness of Traditional Chinese Medicine (TCM) in ameliorating symptoms, including fatigue, poor appetite, abdominal distension, and loose stools, and the reduction rate of these symptoms. spatial genetic structure A record of adverse events was kept throughout the study period. The SAS 94 software package was employed for the data analysis.
Four participants, part of the 200-patient study cohort, withdrew after experiencing the ineffectiveness of the prescribed medication. For reasons of age, three participants were excluded from the investigation. Spontaneous infection The TCM symptom scores of the subjects were not significantly different before the commencement of treatment. After one week of treatment, the full analysis set (FAS) indicated a substantial improvement in efficacy rates for abdominal distension and loose stools within the treatment group, significantly outperforming the control group (p < 0.005). The efficacy of addressing fatigue and poor appetite exhibited no notable disparities between the two groups (p=0.005). The treatment group exhibited a substantially higher rate of fatigue resolution compared to the control group (p<0.005); post-treatment, there were no statistically significant differences between the groups regarding poor appetite, abdominal distention, or loose stools (p>0.005). Substantial improvements in the efficacy of fatigue, poor appetite, abdominal distention, and loose stools were observed in the treated group after two weeks of treatment, significantly exceeding those seen in the control group (p<0.005). A noticeably greater proportion of loose stools cleared in the treatment group, compared to the control group, a statistically significant difference (p=0.005). Yet, a substantial similarity existed in the disappearance rates of fatigue, poor appetite, and abdominal distension between the two sample sets (p=0.005). A complete absence of severely adverse events was reported by the subjects participating in the study.
Xiangsha Liujun pills, according to this clinical trial, effectively alleviated the symptoms of impaired digestive function in convalescent COVID-19 patients.
This clinical investigation highlighted the effectiveness of Xiangsha Liujun pills in alleviating the digestive issues experienced by COVID-19 convalescent patients.
Examining the synergistic mechanisms of Fanmugua (Fructus Caricae) Leaf (CPL) multi-component therapy in treating anemia.
The components' characteristics were established by referencing the literature. Six databases were reviewed in the process of discovering CPL targets. Targets associated with anemia and bone marrow were discovered using enrichment analysis. Hematopoiesis-related pathways and targets were sourced from the Kyoto Encyclopedia of Genes and Genomes database. Investigation of protein-protein interactions resulted in the identification of the key targets. Employing molecular docking, the binding properties of key targets and active components were examined. To evaluate the drug's effectiveness, bone marrow cells served as an experimental model.
A collection of 139 components and 1868 CPL targets were identified through a review of the literature. Target identification, achieved via disease enrichment analysis, resulted in 543 targets for hemorrhagic anemia, 223 targets for aplastic anemia, and 126 targets for sickle cell anemia. Target organ enrichment procedures successfully isolated 27, 29, and 20 bone marrow targets. Analysis of KEGG pathways revealed 47 overlapping hematopoietic pathways and 42 associated targets. Investigations centered on the key components vascular endothelial growth factor A (VEGFA), interleukin 10 (IL-10), platelet-endothelial cell adhesion molecule-1 (PECAM1), C-C motif chemokine 2 (CCL2), and vascular cell adhesion molecule 1 (VCAM1). Among the active constituents of CPL, ursolic acid, quercetin, and hesperidin were identified. Treatment with CPL produced a noteworthy and substantial increase in the expression of VEGFA. VEGFA experienced an impact from the synergistic activity of quercetin and ursolic acid. Quercetin and hesperidin exhibited an effect on VCAM1's activity. The action of quercetin encompassed IL-10, CCL2, VCAM1, and VEGFA. Analysis of cell cultures showed that CPL played a role in increasing the proliferation and migration of bone marrow cells.
Through a synergistic mechanism, CPL's treatment of anemia targets multiple components, affects various pathways, and engages multiple therapeutic targets.
CPL's anemia-treating efficacy is synergistic, arising from its interaction with multiple components, targets, and pathways.
Examining the method by which Buzhong Yigi decoction (BZYQD) reduces prostate cell proliferation and the processes involved.
The eight herbs constituting BZYQD were researched in TCMSP databases, and its predicted targets were collected from the Drugbank database. With GeneCards, Online Mendelian Inheritance in Man (OMIM), and Therapeutic Target Database (TTD) as resources, Benign prostatic hyperplasia (BPH) was used to pinpoint potential targets. A subsequent counter-selection approach was used to isolate the overlapping targets between BZYQD and BPH. The Herb-Compound-Target-Disease network was subsequently constructed with Cytoscape, complemented by a protein interaction network developed using the STRING database's tool for recurring gene neighborhood analysis. To determine the mechanism of the intersection targets, the Database for Annotation, Visualization and Integrated Discovery (DAVID) database was utilized to analyze Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment. To investigate through molecular docking, Mitogen-activated protein kinase 8 (MAPK8), interleukin-6 (IL-6), and quercetin were chosen as targets. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to quantitatively determine the effect of quercetin on the viability of BPH-1 (BPH epithelial cell line) across varied treatment durations (12, 24, 48, and 72 hours) and concentrations (15, 30, 60, and 120 µM). The enzyme-linked immunosorbent assay (ELISA) and quantitative real-time polymerase chain reaction (qRT-PCR) techniques were employed to measure the mRNA expression of IL-6, tumor necrosis factor-alpha (TNF-), IL-1, and other molecules. Employing Western blot methodology, the presence of phospho-p38 mitogen-activated protein kinase (p-P38) and matrix metalloprotein-9 (MMP-9) was evaluated.
BZYQD, composed of 8 herbs and 151 chemical components, shows activity against 1756 targets. 105 common targets with BPH are observed, notably involving MAPK8, IL-6, and further molecules. The GO enrichment analysis generated 352 GO terms (code 005), specifically 208 related to biological process, 64 related to cell component, and 80 related to molecular function. The KEGG pathway enrichment analysis uncovered 20 significant pathways, primarily involving the mechanisms of the MAPK signaling pathway. Quercetin, as indicated by the MTT assay, suppressed the viability of BPH-1 cells in a manner that was both time- and dose-dependent. The administration of quercetin caused a decrease in the production of IL-6, TNF-α, and IL-1, along with a decrease in their mRNA levels, and a significant reduction in the expression of p-P38 and MMP-9.